These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 37298023)
21. Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study. Yang P; Luo H; Zhao L; Xiong F; Tang C J Thorac Dis; 2024 Jul; 16(7):4391-4399. PubMed ID: 39144292 [TBL] [Abstract][Full Text] [Related]
22. Impact of thoracic radiotherapy on first-line treatment outcomes in ES-SCLC patients. Mu X; Zhou Y; Liu Q; Wang J; Xu F; Luo F; Wang K; Li L; Tian P; Li Y; Liu J; Zhang Y; Liu J; Li Y Cancer Med; 2024 Sep; 13(17):e70175. PubMed ID: 39240166 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world. Fang M; Wang L; Gu Q; Wu H; Du X; Lai X Clin Exp Metastasis; 2023 Oct; 40(5):423-429. PubMed ID: 37584783 [TBL] [Abstract][Full Text] [Related]
24. Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis. Qi J; Xu L; Sun J; Wang X; Zhao L Cancer Manag Res; 2019; 11():10767-10775. PubMed ID: 31920386 [TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study. Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y Front Oncol; 2022; 12():894835. PubMed ID: 36203439 [TBL] [Abstract][Full Text] [Related]
26. Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey. Bayman E; Etiz D; Akcay M; Ak G Asian Pac J Cancer Prev; 2014; 15(15):6263-7. PubMed ID: 25124609 [TBL] [Abstract][Full Text] [Related]
27. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer. Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety comparison of PD-1 inhibitors Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464 [TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. Giuliani ME; Atallah S; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ Clin Lung Cancer; 2011 Nov; 12(6):375-9. PubMed ID: 21729647 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis. Li H; Han H; Li C; Wu R; Wang Z; Wang Y; Zhan P; Lv T; Zhang F; Song Y; Liu H Ther Adv Med Oncol; 2023; 15():17588359231189430. PubMed ID: 37885460 [TBL] [Abstract][Full Text] [Related]
31. Role of thoracic radiotherapy in extensive stage small cell lung cancer: a systemic review and meta-analysis. Li AM; Zhou H; Xu YY; Ji XQ; Wu TC; Yuan X; Jiang CC; Zhu XX; Zhan P; Shen ZT Ann Transl Med; 2021 Feb; 9(4):299. PubMed ID: 33708926 [TBL] [Abstract][Full Text] [Related]
32. Higher thoracic radiation dose is beneficial in patients with extensive small cell lung cancer. Yoon HG; Noh JM; Ahn YC; Oh D; Pyo H; Kim H Radiat Oncol J; 2019 Sep; 37(3):185-192. PubMed ID: 31591866 [TBL] [Abstract][Full Text] [Related]
33. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study. Xie J; Chen M; Han H; Xu K; Qiu G; Lin X; Song Y; Ye J; Lv T; Zhan P Thorac Cancer; 2023 May; 14(15):1327-1338. PubMed ID: 37005095 [TBL] [Abstract][Full Text] [Related]
34. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study. Geng N; Ding CM; Liu ZK; Song S; Hu WX Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882 [TBL] [Abstract][Full Text] [Related]
35. A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada. Elegbede AA; Gibson AJ; Fung AS; Cheung WY; Dean ML; Bebb DG; Pabani A JTO Clin Res Rep; 2021 Dec; 2(12):100249. PubMed ID: 34877555 [TBL] [Abstract][Full Text] [Related]
36. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study. Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937 [TBL] [Abstract][Full Text] [Related]
37. Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not? Luo J; Xu L; Zhao L; Cao Y; Pang Q; Wang J; Yuan Z; Wang P Radiat Oncol; 2017 Feb; 12(1):42. PubMed ID: 28245874 [TBL] [Abstract][Full Text] [Related]
38. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy. Qi W; Zhao S; Chen J Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825 [TBL] [Abstract][Full Text] [Related]
39. Metastatic location of extensive stage small-cell lung cancer: implications for thoracic radiation. Zhang H; Deng L; Wang X; Wang D; Teng F; Yu J J Cancer Res Clin Oncol; 2019 Oct; 145(10):2605-2612. PubMed ID: 31410604 [TBL] [Abstract][Full Text] [Related]
40. Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial. Bozorgmehr F; Christopoulos P; Chung I; Cvetkovic J; Feißt M; Krisam J; Schneider MA; Heußel CP; Kreuter M; Müller DW; Thomas M; Rieken S BMC Cancer; 2022 Sep; 22(1):1011. PubMed ID: 36153496 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]